Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|December 23, 2015
Overcoming Specialty Pharmacy Reporting Demands
Author(s)Davy James, Managing Editor
Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can meet the reporting requirements required by manufacturers and payers.
Advertisement
Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can meet the reporting requirements required by manufacturers and payers.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
Increasing Daily Steps Matches Aerobic Training for Asthma Control in Randomized Trial
5